Revusiran (ALN-TTRSC)
ALN-TTRSC-004
Phase 3 small_molecule completed
Quick answer
Revusiran (ALN-TTRSC) for Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) is a Phase 3 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed